SISCAPA and Biognosys Partner to Advance Protein Biomarker Analysis for Clinical Trials
核心洞察
SISCAPA Assay Technologies (搜索) and Biognosys (搜索) have formed an exclusive strategic collaboration to provide end-to-end high-sensitivity protein analysis solutions for biopharma customers from discovery to clinical implementation.
The partnership combines Biognosys (搜索)' TrueDiscovery (搜索) and TrueSignature (搜索) platforms with SISCAPA's antibody-based mass spectrometry technology to achieve unprecedented sensitivity and specificity for biomarker monitoring.
Biopharma companies will benefit from accelerated assay development, enhanced sensitivity for low-abundance biomarkers, and streamlined workflows for translational research and clinical trial applications.
The proteomics landscape is set to transform as SISCAPA Assay Technologies (搜索) and Biognosys (搜索) announced an exclusive strategic collaboration on May 19, 2025. This partnership aims to deliver streamlined end-to-end solutions for high-sensitivity protein analysis, spanning from early biomarker discovery to targeted protein quantification in clinical trials.
The collaboration brings together two leading forces in proteomics: SISCAPA, renowned for its high-sensitivity protein quantitation technology, and Biognosys (搜索), a pioneer in next-generation proteomics services. By integrating their complementary technologies, the companies will offer biopharma customers a comprehensive solution that promises to accelerate biomarker development and enhance clinical trial applications.
Complementary Technologies Creating a Seamless Workflow
Biognosys (搜索)' contribution centers on its TrueDiscovery (搜索) platform, which provides deep, unbiased proteomic insights across various tissues and biological fluids. This platform enables the identification of novel biomarkers that can then be translated into targeted assays using the company's TrueSignature (搜索) platform, which has already demonstrated success in preclinical research and clinical trials with multiple pharmaceutical partners.
SISCAPA's technology brings a different but complementary approach, utilizing highly specific antibodies coupled with mass spectrometry to enrich and quantify target peptides. This method achieves exceptional sensitivity, specificity, and reproducibility, even when working with complex biological samples.
Under the terms of the partnership, Biognosys (搜索) becomes the preferred service provider for SISCAPA's immuno-enrichment technology to biopharma customers, significantly enhancing Biognosys' capabilities in high-sensitivity, high-accuracy, and scalable protein analysis for clinical biomarker monitoring.
Benefits for Biopharma Research and Development
The collaboration offers several key advantages for pharmaceutical companies engaged in biomarker research and drug development:
- A single trusted partner managing the entire workflow from biomarker discovery to clinical implementation
- Accelerated SISCAPA assay development and validation timelines
- Higher sensitivity and specificity for detecting and monitoring low-abundance biomarkers
- Enhanced support for translational research and clinical trial assays
"SISCAPA is extremely pleased to be working with the superb Biognosys (搜索) team to simplify access to the transformational power of protein mass spectrometry from discovery, through drug development, and all the way to clinical biomarker monitoring," said Leigh Anderson, Ph.D., CEO and Founder of SISCAPA Assay Technologies (搜索). "By directly connecting our technologies, we can provide a seamless roadmap for understanding protein biomarkers, targets and drugs."
Oliver Rinner, Ph.D., CEO and Co-Founder of Biognosys (搜索), emphasized the strategic importance of the partnership: "At Biognosys, we are committed to empowering our biopharma partners with the most advanced and robust proteomics solutions, from discovery to clinical application. This collaboration with SISCAPA brings together two world-class teams to create a truly end-to-end workflow for high-sensitivity protein quantification. By integrating our strengths, we are enabling customers to accelerate biomarker development and confidently translate their discoveries into impactful clinical insights."
Implications for Clinical Proteomics
The partnership addresses a significant challenge in the field of proteomics: the need for seamless translation of biomarker discoveries into validated clinical assays. By bridging the gap between discovery and clinical application, the collaboration could potentially accelerate the development of protein biomarkers for disease diagnosis, patient stratification, and therapeutic monitoring.
For clinical trials specifically, this integrated approach offers the potential for more precise patient selection and treatment response monitoring, potentially improving trial outcomes and accelerating drug development timelines.
With laboratories near Zurich, Switzerland, and Boston, Massachusetts, Biognosys (搜索) is well-positioned to support global biopharma customers with this enhanced service offering. Meanwhile, SISCAPA's expertise in high-sensitivity protein quantitation through mass spectrometry-based workflows complements Biognosys' capabilities, creating a comprehensive solution for the proteomics needs of the pharmaceutical industry.
As protein biomarkers continue to gain importance in precision medicine and drug development, this strategic collaboration represents a significant advancement in the tools available to researchers and clinicians working to translate proteomic discoveries into clinical applications.